Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 10:2022:4600145.
doi: 10.1155/2022/4600145. eCollection 2022.

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

Li Sun  1 , Caixia Liu  2 , Yun Li  3
Affiliations

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

Li Sun et al. Comput Math Methods Med. .

Retraction in

Abstract

Objective: This study was aimed at investigating the efficacy of PARP inhibitor combined with bevacizumab in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma.

Methods: A total of 84 patients with platinum-resistant recurrent ovarian epithelial carcinoma treated in our hospital from May 2017 to June 2018 were selected as the research objects. The patients were divided into observation group (n = 42) and control group (n = 42) according to random number table method. The observation group was treated with olaparib combined with bevacizumab, while the control group was treated with albumin-bound paclitaxel combined with bevacizumab, and the clinical efficacy of the two groups was observed. The levels of serum carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199), and epididymal protein 4 (HE4) were determined. The levels of miRNA124, mirNA-21, and miRNA-203 in the two groups were detected. The incidence of adverse reactions was compared between the two groups. The quality of life of the two groups was assessed using FACT-G scale. The drug safety of the two groups was observed. All patients were followed up for 3 years, and the survival time of the two groups was recorded. The Kaplan-Meier method was used to analyze the survival of the two groups.

Results: The overall response rate (ORR) (69.05%) and disease control rate (DCR) (88.10%) of the observation group were higher than those of the control group (40.48% and 66.67%), and the differences were statistically significant (both P < 0.05). After treatment, the levels of serum CA125, CA199, HE4, miRNA124, miRNA-21, and miRNA-203 and the improvement degree of quality of life score in the observation group were greater than those in the control group, with statistical significances (all P < 0.05).The 1-year, 2-year, and 3-year survival rates of the observation group (97.62%, 88.10%, and 80.95%) were higher than those of the control group (71.43%, 57.14%, and 47.62%), with statistical significances (all P > 0.05).

Conclusion: PARP inhibitor combined with bevacizumab had good effect in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma and can effectively improve the survival time and quality of life of patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
1-year survival curve of the observation group and the control group.
Figure 2
Figure 2
2-year survival curve of the observation group and the control group.
Figure 3
Figure 3
3-year survival curve of the observation group and the control group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kroeger P. T., Jr., Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics & Gynecology . 2017;29(1):26–34. doi: 10.1097/gco.0000000000000340. - DOI - PMC - PubMed
    1. Odunsi K. Immunotherapy in ovarian cancer. Annals of Oncology . 2017;28(8):viii1–viii7. doi: 10.1093/annonc/mdx444. - DOI - PMC - PubMed
    1. Lheureux S., Cristea M. C., Bruce J. P., et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet . 2021;397(10271):281–292. doi: 10.1016/s0140-6736(20)32554-x. - DOI - PMC - PubMed
    1. Konstantinopoulos P. A., Waggoner S., Vidal G. A., et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncology . 2019;5(8):1141–1149. doi: 10.1001/jamaoncol.2019.1048. - DOI - PMC - PubMed
    1. van Zyl B., Tang D., Bowden N. A. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-Related Cancer . 2018;25(5):303–318. doi: 10.1530/erc-17-0336. - DOI - PubMed

Publication types

MeSH terms